Selective inhibition of sleep related growth hormone release by Phe-4-somatostatin

J. A. Cabranes, A. Vela, F. Timoneda, C. A. Meyers, D. H. Coy, Andrew V Schally, A. L. Charro

Research output: Contribution to journalArticle

Abstract

We have compared the effects of somatostatin (SS) and the somatostatin analog Phe-4-Ss on nocturnal GH secretion in three normal male volunteers, 20 to 23 years of age. Subjects were studied in our sleep laboratory on 5 consecutive nights. Nights 1 and 2 were used for adaptation. On the third night (control night), all patients exhibited a typical GH peak accompanying slow-wave sleep, with maximum GH levels from 9.2 to 27 ng/ml. Insulin, glucagon and glucose levels were episodic and sleep-independent. On night 4, subjects received SS infusion at a rate of 3 μg/min, which inhibited GH levels consistently below 2.4 ng/ml. In two cases a post-infusion rebound of GH levels was observed. During SS infusion all three subjects showed a significant decrease in insulin levels (p < 0.0005), followed by an immediate rebound after infusion was stopped. Glucagon levels fell significantly during infusion (p < 0.001, p < 0.025 and p < 0.00025 respectively). Glucose was significantly higher than on the control night in subject No. 3 (p < 0.0005) and similar to the control night in subjects 1 and 2. On the fifth night, Phe-4-SS was infused at a rate of 0.75 μg/min. GH levels decreased significantly as compared to the control night in all three subjects and remained virtually constant throughout the night. Insulin levels were diminished in subject No. 1 (p < 0.0005), but were comparable to control values in subjects 2 and 3. Cessation of analog infusion was followed by a rebound in insulin levels in all three subjects. Glucagon values were not significantly lowered and the rebound effect was not apparent. Glucose levels were higher in response to Phe-4-SS than on the control night, and fell below infusion values (p < 0.001) after administration was discontinued. It was concluded that Phe-4-SS inhibits nocturnal secretion of GH more selectively than SS, but its effect is not more prolonged than that of SS.

Original languageEnglish
Pages (from-to)421-431
Number of pages11
JournalResearch Communications in Chemical Pathology and Pharmacology
Volume45
Issue number3
StatePublished - Nov 15 1984
Externally publishedYes

Fingerprint

Somatostatin
Growth Hormone
Sleep
Glucagon
Insulin
Glucose
Healthy Volunteers
Phe(4)-somatostatin
Inhibition (Psychology)

ASJC Scopus subject areas

  • Toxicology
  • Pharmacology

Cite this

Cabranes, J. A., Vela, A., Timoneda, F., Meyers, C. A., Coy, D. H., Schally, A. V., & Charro, A. L. (1984). Selective inhibition of sleep related growth hormone release by Phe-4-somatostatin. Research Communications in Chemical Pathology and Pharmacology, 45(3), 421-431.

Selective inhibition of sleep related growth hormone release by Phe-4-somatostatin. / Cabranes, J. A.; Vela, A.; Timoneda, F.; Meyers, C. A.; Coy, D. H.; Schally, Andrew V; Charro, A. L.

In: Research Communications in Chemical Pathology and Pharmacology, Vol. 45, No. 3, 15.11.1984, p. 421-431.

Research output: Contribution to journalArticle

Cabranes, JA, Vela, A, Timoneda, F, Meyers, CA, Coy, DH, Schally, AV & Charro, AL 1984, 'Selective inhibition of sleep related growth hormone release by Phe-4-somatostatin', Research Communications in Chemical Pathology and Pharmacology, vol. 45, no. 3, pp. 421-431.
Cabranes, J. A. ; Vela, A. ; Timoneda, F. ; Meyers, C. A. ; Coy, D. H. ; Schally, Andrew V ; Charro, A. L. / Selective inhibition of sleep related growth hormone release by Phe-4-somatostatin. In: Research Communications in Chemical Pathology and Pharmacology. 1984 ; Vol. 45, No. 3. pp. 421-431.
@article{9d46f34bc61d42a7a64d61b7dcd9957b,
title = "Selective inhibition of sleep related growth hormone release by Phe-4-somatostatin",
abstract = "We have compared the effects of somatostatin (SS) and the somatostatin analog Phe-4-Ss on nocturnal GH secretion in three normal male volunteers, 20 to 23 years of age. Subjects were studied in our sleep laboratory on 5 consecutive nights. Nights 1 and 2 were used for adaptation. On the third night (control night), all patients exhibited a typical GH peak accompanying slow-wave sleep, with maximum GH levels from 9.2 to 27 ng/ml. Insulin, glucagon and glucose levels were episodic and sleep-independent. On night 4, subjects received SS infusion at a rate of 3 μg/min, which inhibited GH levels consistently below 2.4 ng/ml. In two cases a post-infusion rebound of GH levels was observed. During SS infusion all three subjects showed a significant decrease in insulin levels (p < 0.0005), followed by an immediate rebound after infusion was stopped. Glucagon levels fell significantly during infusion (p < 0.001, p < 0.025 and p < 0.00025 respectively). Glucose was significantly higher than on the control night in subject No. 3 (p < 0.0005) and similar to the control night in subjects 1 and 2. On the fifth night, Phe-4-SS was infused at a rate of 0.75 μg/min. GH levels decreased significantly as compared to the control night in all three subjects and remained virtually constant throughout the night. Insulin levels were diminished in subject No. 1 (p < 0.0005), but were comparable to control values in subjects 2 and 3. Cessation of analog infusion was followed by a rebound in insulin levels in all three subjects. Glucagon values were not significantly lowered and the rebound effect was not apparent. Glucose levels were higher in response to Phe-4-SS than on the control night, and fell below infusion values (p < 0.001) after administration was discontinued. It was concluded that Phe-4-SS inhibits nocturnal secretion of GH more selectively than SS, but its effect is not more prolonged than that of SS.",
author = "Cabranes, {J. A.} and A. Vela and F. Timoneda and Meyers, {C. A.} and Coy, {D. H.} and Schally, {Andrew V} and Charro, {A. L.}",
year = "1984",
month = "11",
day = "15",
language = "English",
volume = "45",
pages = "421--431",
journal = "Research Communications in Molecular Pathology and Pharmacology",
issn = "0034-5164",
publisher = "PJD Publications Ltd",
number = "3",

}

TY - JOUR

T1 - Selective inhibition of sleep related growth hormone release by Phe-4-somatostatin

AU - Cabranes, J. A.

AU - Vela, A.

AU - Timoneda, F.

AU - Meyers, C. A.

AU - Coy, D. H.

AU - Schally, Andrew V

AU - Charro, A. L.

PY - 1984/11/15

Y1 - 1984/11/15

N2 - We have compared the effects of somatostatin (SS) and the somatostatin analog Phe-4-Ss on nocturnal GH secretion in three normal male volunteers, 20 to 23 years of age. Subjects were studied in our sleep laboratory on 5 consecutive nights. Nights 1 and 2 were used for adaptation. On the third night (control night), all patients exhibited a typical GH peak accompanying slow-wave sleep, with maximum GH levels from 9.2 to 27 ng/ml. Insulin, glucagon and glucose levels were episodic and sleep-independent. On night 4, subjects received SS infusion at a rate of 3 μg/min, which inhibited GH levels consistently below 2.4 ng/ml. In two cases a post-infusion rebound of GH levels was observed. During SS infusion all three subjects showed a significant decrease in insulin levels (p < 0.0005), followed by an immediate rebound after infusion was stopped. Glucagon levels fell significantly during infusion (p < 0.001, p < 0.025 and p < 0.00025 respectively). Glucose was significantly higher than on the control night in subject No. 3 (p < 0.0005) and similar to the control night in subjects 1 and 2. On the fifth night, Phe-4-SS was infused at a rate of 0.75 μg/min. GH levels decreased significantly as compared to the control night in all three subjects and remained virtually constant throughout the night. Insulin levels were diminished in subject No. 1 (p < 0.0005), but were comparable to control values in subjects 2 and 3. Cessation of analog infusion was followed by a rebound in insulin levels in all three subjects. Glucagon values were not significantly lowered and the rebound effect was not apparent. Glucose levels were higher in response to Phe-4-SS than on the control night, and fell below infusion values (p < 0.001) after administration was discontinued. It was concluded that Phe-4-SS inhibits nocturnal secretion of GH more selectively than SS, but its effect is not more prolonged than that of SS.

AB - We have compared the effects of somatostatin (SS) and the somatostatin analog Phe-4-Ss on nocturnal GH secretion in three normal male volunteers, 20 to 23 years of age. Subjects were studied in our sleep laboratory on 5 consecutive nights. Nights 1 and 2 were used for adaptation. On the third night (control night), all patients exhibited a typical GH peak accompanying slow-wave sleep, with maximum GH levels from 9.2 to 27 ng/ml. Insulin, glucagon and glucose levels were episodic and sleep-independent. On night 4, subjects received SS infusion at a rate of 3 μg/min, which inhibited GH levels consistently below 2.4 ng/ml. In two cases a post-infusion rebound of GH levels was observed. During SS infusion all three subjects showed a significant decrease in insulin levels (p < 0.0005), followed by an immediate rebound after infusion was stopped. Glucagon levels fell significantly during infusion (p < 0.001, p < 0.025 and p < 0.00025 respectively). Glucose was significantly higher than on the control night in subject No. 3 (p < 0.0005) and similar to the control night in subjects 1 and 2. On the fifth night, Phe-4-SS was infused at a rate of 0.75 μg/min. GH levels decreased significantly as compared to the control night in all three subjects and remained virtually constant throughout the night. Insulin levels were diminished in subject No. 1 (p < 0.0005), but were comparable to control values in subjects 2 and 3. Cessation of analog infusion was followed by a rebound in insulin levels in all three subjects. Glucagon values were not significantly lowered and the rebound effect was not apparent. Glucose levels were higher in response to Phe-4-SS than on the control night, and fell below infusion values (p < 0.001) after administration was discontinued. It was concluded that Phe-4-SS inhibits nocturnal secretion of GH more selectively than SS, but its effect is not more prolonged than that of SS.

UR - http://www.scopus.com/inward/record.url?scp=0021181894&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021181894&partnerID=8YFLogxK

M3 - Article

C2 - 6150528

AN - SCOPUS:0021181894

VL - 45

SP - 421

EP - 431

JO - Research Communications in Molecular Pathology and Pharmacology

JF - Research Communications in Molecular Pathology and Pharmacology

SN - 0034-5164

IS - 3

ER -